MOUNTAIN VIEW, Calif.,
Aug. 20, 2015 /PRNewswire/
-- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of
medication and supply management solutions to healthcare systems,
today announced that Peter Kuipers
has joined the company as Executive Vice President, Chief Financial
Officer. Mr. Kuipers brings 20 years of financial and business
strategy leadership experience in high tech, manufacturing, and
international markets. As announced in February, current CFO
Rob Seim now completes the
transition to his new role as Executive Vice President,
International and Global Quality & Manufacturing.
"Peter offers a unique blend of industry experience that will
make him a valuable addition to our executive team as we look to
solidify our position as a leader in the U.S. and expand
international opportunities," said Randall
Lipps, Omnicell president, chairman, and CEO. "Peter's
experience will help to advance the company's focus on growth
through differentiated products, new markets, and acquisitions," he
said.
Prior to joining Omnicell, Mr. Kuipers served as Senior Vice
President and Chief Financial Officer at Quantcast Corporation, a
world leader in applying the power of big data and analytics to
digital audience measurement and advertising. Previously Mr.
Kuipers served as Executive Vice President and CFO at The Weather
Company (TWC), operating The Weather Channel, weather.com,
wunderground.com and and its professional services division
WSI.
Prior to TWC, Mr. Kuipers served in various financial leadership
roles at Yahoo!, including for the company's largest geographical
region as Vice President of Finance for the Americas, a
multibillion-dollar business, and led teams responsible for
Financial Planning and Analysis, Business Finance, Accounting, and
Reporting for the region across multiple product lines and
channels. At Yahoo! he also previously served as Vice President of
Finance for the Global Products division and as Vice President of
Finance for International Regions.
Previously Mr. Kuipers served in senior financial leadership
roles at Altera Corporation, General Electric Company, and Akzo
Nobel. He started his career with Ernst & Young in
The Netherlands and Seattle WA.
He holds a Master's Degree in Economics and Business
Administration from the Maastricht
University School of Business and Economics in the Netherlands. He is also a Chartered
Accountant in the Netherlands.
"Medication and supply management in health care is undergoing a
transformation driven by the power of data and automation
technology," said Mr. Kuipers. "Omnicell is well positioned to
provide industry-leading levels of quality and safety to medication
management solutions globally and I am proud to be joining one of
the industry's leading innovators."
"As I move into a new role centered around our international
markets, I'm pleased to welcome Peter to the role of CFO," shared
Rob Seim. "In an age where
international hospitals and health systems are looking to mirror
best practices developed by hospitals in the U.S., I'm excited to
evaluate and meet the needs of potential customers abroad."
"Since joining us in 2006 Rob has done a terrific job as our
CFO, where he has led many of our efforts that resulted in a
quadrupling of the revenue and growth of operating income from 6%
to 15%. We're excited about his willingness to take on this
expanded role that is core to our continued growth, and appreciate
his ongoing commitment and dedication to Omnicell," said Mr.
Lipps.
About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been creating new
efficiencies to improve patient care, anywhere it is delivered.
Omnicell is a leading supplier of comprehensive automation and
business analytics software for patient-centric medication and
supply management across the entire health care continuum—from the
acute care hospital setting to post-acute skilled nursing and
long-term care facilities to the home.
More than 3,000 customers worldwide have utilized Omnicell
Automation and Analytics solutions to increase operational
efficiency, reduce errors, deliver actionable intelligence and
improve patient safety. Omnicell Medication Adherence solutions,
including its MTS Medication Technologies brand, provide innovative
medication adherence packaging solutions to help reduce costly
hospital readmissions. In addition, these solutions enable
approximately 6,000 institutional and retail pharmacies worldwide
to maintain high accuracy and quality standards in medication
dispensing and administration while optimizing productivity and
controlling costs.
For more information about Omnicell, Inc. please visit
www.omnicell.com.
Forward-Looking Statements
To the extent any statements contained in this release deal with
information that is not historical, these statements are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. As such, they are subject
to the occurrence of many events outside Omnicell's control and are
subject to various risk factors that could cause actual results to
differ materially from those expressed or implied in any
forward-looking statement. Such statements include, but are not
limited to the success of Omnicell's executive team, Omnicell's
U.S. strategy and Omnicell's expansion of international
opportunities. Risks that contribute to the uncertain nature of the
forward-looking statements include our ability to take advantage of
the growth opportunities in medication management across the
spectrum of healthcare settings from long term care to home care,
unfavorable general economic and market conditions, risks to growth
and acceptance of our products and services, including competitive
conversions, and to growth of the clinical automation and workflow
automation market generally, the potential of increasing
competition, potential regulatory changes, the ability of the
company to improve sales productivity to grow product bookings, to
develop new products and to acquire and successfully integrate
companies. These and other risks and uncertainties are described
more fully in Omnicell's most recent filings with the Securities
and Exchange Commission. Prospective investors are cautioned not to
place undue reliance on forward-looking statements. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Omnicell undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
OMCL-G
Editor's Notes:
- All Omnicell news releases (financial, acquisitions, products,
technology etc.) are issued exclusively by PR Newswire and are
immediately thereafter posted on the company's external website,
omnicell.com.
- Omnicell and the Omnicell logo design are registered trademarks
of Omnicell, Inc.
- All other brand or product names may be trademarks or
registered trademarks of their respective companies.
Logo -
http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/omnicell-appoints-peter-kuipers-as-chief-financial-officer-300131226.html
SOURCE Omnicell, Inc.